Derek T Hayden1, Niamh Hannon2, Elizabeth Callaly2, Danielle Ní Chróinín2, Gillian Horgan2, Lorraine Kyne2, Joseph Duggan2, Eamon Dolan2, Killian O'Rourke2, David Williams2, Sean Murphy2, Peter J Kelly2. 1. From the Stroke Department (D.T.H., E.C., D.N.C., G.H., K.O., S.M., P.J.K.), and Geriatrics Department (L.K., J.D.), Neurovascular Unit for Applied Translational Research and Therapeutics, University College Dublin/Dublin Academic Medical Centre, Mater University Hospital, Dublin, Ireland; Stroke Department, Beaumont University Hospital, Dublin, Ireland (D.W.); Stroke Department, Connolly Hospital Blanchardstown, Dublin, Ireland (E.C., E.D.); Department of Neurosciences, Addenbrookes Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom (N.H.); and Stroke Department, Royal College of Surgeons, Dublin, Ireland (D.W., S.M.). dhayden@mater.ie. 2. From the Stroke Department (D.T.H., E.C., D.N.C., G.H., K.O., S.M., P.J.K.), and Geriatrics Department (L.K., J.D.), Neurovascular Unit for Applied Translational Research and Therapeutics, University College Dublin/Dublin Academic Medical Centre, Mater University Hospital, Dublin, Ireland; Stroke Department, Beaumont University Hospital, Dublin, Ireland (D.W.); Stroke Department, Connolly Hospital Blanchardstown, Dublin, Ireland (E.C., E.D.); Department of Neurosciences, Addenbrookes Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom (N.H.); and Stroke Department, Royal College of Surgeons, Dublin, Ireland (D.W., S.M.).
Abstract
BACKGROUND AND PURPOSE: Demographic trends in atrial fibrillation (AF) incidence may yield a substantial rise in the societal burden of AF-related stroke (AF-stroke). Accurate population-wide outcome data are essential to inform health service planning to improve AF-stroke prevention, and provision of rehabilitation, nursing home, and community supports for AF-stroke survivors. METHODS: We investigated rates and determinants of 5-year fatality, stroke recurrence, functional outcomes, and prescribing of secondary prevention medications in AF-stroke in the North Dublin Population Stroke Study. Ascertainment included hot and cold pursuit using multiple overlapping sources. Survival analysis was performed using lifetables and Kaplan-Meier survival curves, and Cox proportional hazard modeling was performed to identify predictors of death and recurrent stroke. RESULTS: Five hundred sixty-eight patients with new stroke were identified, including 177 (31.2%) AF-stroke. At 5 years, 39.2% (confidence interval, 31.5-46.8) of ischemic AF-stroke patients were alive. Congestive heart failure, hypertension, age <65, 65-74 years, and ≥75 years, diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism, vascular disease and female sex (CHA2DS2-VASc) score (hazard ratio [HR], 1.34; P<0.001), CHADS2 score (HR 1.42, P=0.004), National Institute of Health Stroke Scale (HR, 1.09; P<0.0001), and subtherapeutic international normalized ratio (<2.0) at stroke onset (HR, 3.29; P=0.003) were independently associated with 5-year fatality, whereas warfarin (HR, 0.40; P=0.001) and statin use after index stroke (HR, 0.52; P=0.005) were associated with improved survival. The 5-year recurrence rate after ischemic AF-stroke was 21.5% (confidence interval, 14.5-31.3). Trends toward greater risk of recurrence were observed for persistent AF (HR, 3.09; P=0.07) and CHA2DS2-VASc score (HR, 1.34; P=0.07). Nursing home care was needed for 25.9% of patients. CONCLUSIONS: AF-stroke is associated with considerable long-term morbidity, fatality, stroke recurrence, and nursing home requirement. Adequately resourced national AF strategies to improve AF detection and prevention are needed.
BACKGROUND AND PURPOSE: Demographic trends in atrial fibrillation (AF) incidence may yield a substantial rise in the societal burden of AF-related stroke (AF-stroke). Accurate population-wide outcome data are essential to inform health service planning to improve AF-stroke prevention, and provision of rehabilitation, nursing home, and community supports for AF-stroke survivors. METHODS: We investigated rates and determinants of 5-year fatality, stroke recurrence, functional outcomes, and prescribing of secondary prevention medications in AF-stroke in the North Dublin Population Stroke Study. Ascertainment included hot and cold pursuit using multiple overlapping sources. Survival analysis was performed using lifetables and Kaplan-Meier survival curves, and Cox proportional hazard modeling was performed to identify predictors of death and recurrent stroke. RESULTS: Five hundred sixty-eight patients with new stroke were identified, including 177 (31.2%) AF-stroke. At 5 years, 39.2% (confidence interval, 31.5-46.8) of ischemic AF-strokepatients were alive. Congestive heart failure, hypertension, age <65, 65-74 years, and ≥75 years, diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism, vascular disease and female sex (CHA2DS2-VASc) score (hazard ratio [HR], 1.34; P<0.001), CHADS2 score (HR 1.42, P=0.004), National Institute of Health Stroke Scale (HR, 1.09; P<0.0001), and subtherapeutic international normalized ratio (<2.0) at stroke onset (HR, 3.29; P=0.003) were independently associated with 5-year fatality, whereas warfarin (HR, 0.40; P=0.001) and statin use after index stroke (HR, 0.52; P=0.005) were associated with improved survival. The 5-year recurrence rate after ischemic AF-stroke was 21.5% (confidence interval, 14.5-31.3). Trends toward greater risk of recurrence were observed for persistent AF (HR, 3.09; P=0.07) and CHA2DS2-VASc score (HR, 1.34; P=0.07). Nursing home care was needed for 25.9% of patients. CONCLUSIONS:AF-stroke is associated with considerable long-term morbidity, fatality, stroke recurrence, and nursing home requirement. Adequately resourced national AF strategies to improve AF detection and prevention are needed.
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Kevin G Graves; Victoria Jacobs; Heidi T May; Michael J Cutler; John D Day; T Jared Bunch Journal: Curr Treat Options Cardiovasc Med Date: 2018-01-24
Authors: Darae Ko; Jonathan L Thigpen; James A Otis; Kristen Forster; Lori Henault; Emily Quinn; Yorghos Tripodis; Peter B Berger; Nita Limdi; Elaine M Hylek Journal: Int J Cardiol Date: 2016-10-24 Impact factor: 4.164
Authors: Muhammad Bilal Munir; Muhammad Zia Khan; Douglas Darden; Deepak K Pasupula; Sudarshan Balla; Frederick T Han; Ryan Reeves; Jonathan C Hsu Journal: J Cardiovasc Electrophysiol Date: 2020-11-11